https://www.curelaboncology.com/david-j-shulkin-m-d/2020-11-24T10:03:35+00:00https://www.curelaboncology.com/curelab-oncology-establishes-operations-in-the-gulf-region/2020-11-24T10:03:09+00:00https://www.curelaboncology.com/curelab-oncology-establishes-operations-in-europe/2020-11-24T10:02:40+00:00https://www.curelaboncology.com/a-disruptive-approach-to-oncology-therapy-development/2020-11-11T18:35:46+00:00https://www.curelaboncology.com/curelab-oncology-receives-pre-ind-response-from-fda-regarding-planned-trial-for-triple-negative-breast-cancer/2020-11-24T10:04:00+00:00https://www.curelaboncology.com/curelab-oncologys-dr-alex-shneider-publishes-paper-can-melatonin-reduce-the-severity-of-covid-19/2021-08-11T21:42:24+00:00https://www.curelaboncology.com/curelab-oncology-launches-veterinary-oncology-sister-company-curelab-veterinary/2022-07-21T13:08:22+00:00https://www.curelaboncology.com/curelab-oncology-adds-hong-kong-to-expanding-scope-of-patent-protection/2022-04-27T17:31:57+00:00https://www.curelaboncology.com/curelab-oncology-submits-patent-for-covid-therapeutic-ahead-of-phase-i-clinical-trials/2021-06-30T11:50:12+00:00https://www.curelaboncology.com/curelab-oncology-granted-us-patent-for-therapeutic-use-of-its-lead-product-in-als-alzheimers-huntingtons-and-parkinsons-diseases/2021-07-20T15:31:45+00:00https://www.curelaboncology.com/hormone-resistant/2021-08-12T14:37:06+00:00https://www.curelaboncology.com/curelab-oncology-presents-at-2021-esmo-congress/2021-09-20T17:08:21+00:00https://www.curelaboncology.com/oncologytube-interviews-dr-alex-shneider-of-curelab-oncology-and-prof-sergei-krasny/2021-11-23T09:38:28+00:00https://www.curelaboncology.com/curelab-oncology-secures-patent-protection-in-india/2021-11-24T22:02:40+00:00https://www.curelaboncology.com/curelab-oncology-and-the-american-eurasian-cancer-alliance-partner-to-fight-ovarian-cancer/2022-01-31T07:34:52+00:00https://www.curelaboncology.com/the-scientist-russian-scientists-grapple-with-an-uncertain-future/2022-03-31T14:30:01+00:00https://www.curelaboncology.com/university-of-camerino-signs-strategic-partnership-with-curelab-veterinary-to-revolutionize-cancer-treatment-for-companion-animals/2024-03-13T09:12:52+00:00https://www.curelaboncology.com/curelab-oncology-secures-patent-protection-for-p62-plasmid-therapeutic-in-south-korea/2024-03-13T09:08:11+00:00https://www.curelaboncology.com/esmo-2022-interim-results-for-treatment-of-platinum-resistant-ovarian-cancer-with-p62-plasmid-dna-show-statistically-significant-changes-in-progression-free-survival/2022-09-10T12:28:35+00:00https://www.curelaboncology.com/biotech-internship-opportunity-fda-usda-liaison/2022-11-05T11:16:55+00:00https://www.curelaboncology.com/curelab-receives-3m-from-prominent-biotech-investor-dr-john-ballantyne/2023-03-04T00:03:28+00:00https://www.curelaboncology.com/curelab-oncology-secures-patent-protection-for-p62-plasmid-therapeutic-in-india/2023-07-16T21:28:15+00:00https://www.curelaboncology.com/curelab-seeks-new-strategic-partners-to-bring-cancer-innovation-to-market/2024-03-14T00:18:08+00:00https://www.curelaboncology.com/elenagennew/2024-03-19T15:30:24+00:00https://www.curelaboncology.com/dna-therapy-effective-against-chemo-resistant-ovarian-cancer/2024-03-19T14:41:15+00:00https://www.curelaboncology.com/study-undermines-mechanism-based-discovery-says-curelab/2024-03-19T14:39:58+00:00https://www.curelaboncology.com/novel-dna-vaccine-elenagen-demonstrates-promising-clinical-results/2024-03-19T15:32:05+00:00https://www.curelaboncology.com/elenagen-a-novel-dna-immunotherapy-for-the-deadliest-form-of-ovarian-cancer-delays-disease-progression/2024-03-20T09:25:07+00:00https://www.curelaboncology.com/curelab-oncology-secures-patent-protection-in-canada-for-elenagen-its-p62-plasmid-cancer-therapeutic/2024-03-23T10:23:29+00:00https://www.curelaboncology.com/healing-by-proxy-newly-discovered-drug-elenagen-may-treat-cancer-and-inflammation-through-indirect-action/2024-06-14T17:12:35+00:00https://www.curelaboncology.com/breakthroughs-and-challenges-in-therapeutic-cancer-vaccines-a-new-era-of-hope/2024-06-20T09:25:58+00:00https://www.curelaboncology.com/curelab-oncology-files-patent-application-for-groundbreaking-wound-healing-therapy/2024-11-19T17:45:32+00:00https://www.curelaboncology.com/curelab-ceo-dr-alexander-shneider-unveils-promising-cancer-treatment-at-2024-medinvest-conference/2024-10-29T18:05:13+00:00https://www.curelaboncology.com/curelab-oncologys-elenagen-dna-vaccine-shows-promise-in-immuno-oncology-and-beyond/2024-11-13T22:51:40+00:00https://www.curelaboncology.com/curelab-oncology-seeks-to-revolutionize-chronic-pain-management-with-novel-p62-based-therapy/2024-11-19T17:59:57+00:00https://www.curelaboncology.com/curelab-oncologys-ceo-shares-insights-on-biotech-entrepreneurship/2024-11-29T17:13:05+00:00https://www.curelaboncology.com/digital-journal-highlights-curelab-oncologys-innovative-approach-with-elenagen/2024-11-29T17:30:53+00:00https://www.curelaboncology.com/elenagens-indirect-mechanism-offers-new-hope-in-cancer-and-inflammation-treatment/2024-11-29T17:35:24+00:00https://www.curelaboncology.com/curelab-oncology-highlighted-in-labiotechs-deep-dive-on-ovarian-cancer-vaccines/2024-12-25T19:31:07+00:00https://www.curelaboncology.com/can-a-polarized-biomedical-community-reform-drug-development-policies-while-maintaining-nuance-and-moderation/2025-02-25T10:52:48+00:00https://www.curelaboncology.com/investigational-anti-cancer-dna-therapy-eases-chronic-osteoarthritis-pain-in-dogs-pointing-to-a-new-non-opioid-path-for-humans/2025-08-10T20:28:44+00:00https://www.curelaboncology.com/could-a-stem-cell-arthritis-treatment-for-dogs-work-in-humans-pain-news-network-explores-elenagens-promise/2025-08-14T09:42:01+00:00https://www.curelaboncology.com/investigational-anti-cancer-dna-therapy-eases-chronic-osteoarthritis-pain-in-dogs-pointing-to-a-new-non-opioid-path-for-humans-2/2025-08-14T09:44:30+00:00https://www.curelaboncology.com/qa-meet-gabriel-levin-md-curelab-oncologys-director-of-oncology/2025-09-26T20:05:09+00:00https://www.curelaboncology.com/following-the-unexpected-signals-in-cancer-research-dr-alexander-shneider-ph-d/2026-02-20T21:34:25+00:00https://www.curelaboncology.com/elenagen-helps-women-with-ovarian-cancer-live-1-year-longer/2026-02-20T22:34:07+00:00https://www.curelaboncology.com/dna-therapy-doubles-ovarian-cancer-survival/2026-02-20T22:58:32+00:00https://www.curelaboncology.com/survival-rates-near-double-with-experimental-therapy-in-ovarian-cancer/2026-02-20T23:07:16+00:00https://www.curelaboncology.com/experimental-drug-doubles-survival-of-ovarian-cancer-patients-in-trial/2026-02-20T23:26:21+00:00https://www.curelaboncology.com/health-rounds-experimental-drug-doubles-survival-of-ovarian-cancer-patients-in-trial/2026-02-21T08:28:19+00:00https://www.curelaboncology.com/un-farmaco-experimental-duplica-la-supervivencia-en-cancer-de-ovario-resistente/2026-02-21T08:40:12+00:00https://www.curelaboncology.com/cancer-de-lovaire-avance-ce-traitement-experimental-a-presque-double-la-survie-de-patientes-quon-pensait-condamnees/2026-02-21T08:51:46+00:00https://www.curelaboncology.com/experimental-drug-doubles-ovarian-cancer-survival/2026-02-21T09:37:48+00:00https://www.curelaboncology.com/health-rounds-experimental-drug-doubles-survival-of-ovarian-cancer-patients-in-trial-2/2026-02-21T09:46:55+00:00https://www.curelaboncology.com/health-rounds-experimental-drug-doubles-survival-of-ovarian-cancer-patients-in-trial-msn/2026-02-21T10:10:23+00:00https://www.curelaboncology.com/health-rounds-experimental-drug-doubles-survival-of-ovarian-cancer-patients-in-trial-reuters/2026-02-21T10:19:04+00:00https://www.curelaboncology.com/health-rounds-experimental-drug-doubles-survival-of-ovarian-cancer-patients-in-trial-regional-media-news/2026-02-21T10:26:50+00:00https://www.curelaboncology.com/new-hope-for-ovarian-cancer-with-alexander-schneider/2026-02-23T16:48:56+00:00https://www.curelaboncology.com/rondes-de-sante-un-medicament-experimental-double-la-survie-des-patientes-atteintes-dun-cancer-de-lovaire/2026-02-23T17:21:41+00:00https://www.curelaboncology.com/breakthrough-phase-ii-study-in-platinum-resistant-ovarian-cancer-set-for/2026-02-23T19:14:50+00:00https://www.curelaboncology.com/overall-survival-benefit-with-elenagen-plus-gemcitabine-in-platinum-resistant-ovarian-cancer/2026-02-23T19:14:12+00:00https://www.curelaboncology.com/elenagen-plus-gemcitabine-improves-overall-survival-for-patients-with-platinum-resistant-ovarian-cancer/2026-02-23T19:35:38+00:00https://www.curelaboncology.com/hmn-2026-how-a-novel-dna-based-therapy-achieves-significant-increase-in-overall-survival-in-platinum-resistant-ovarian-cancer/2026-02-23T21:02:30+00:00https://www.curelaboncology.com/ddw-highlights-20-january-2026/2026-02-23T21:24:19+00:00https://www.curelaboncology.com/therapy-could-increase-ovarian-cancer-survival-paper-finds-drug-discovery-world-ddw/2026-02-24T07:33:27+00:00https://www.curelaboncology.com/novel-dna-based-therapy-achieves-reduction-in-mortality-in-resistant-ovarian-cancer/2026-02-24T07:41:10+00:00https://www.curelaboncology.com/a-novel-dna-based-therapy-achieves-significant-increase-in-overall-survival-in-platinum-resistant-ovarian-cancer/2026-02-24T07:50:37+00:00https://www.curelaboncology.com/novel-dna-based-therapy-called-elenagen-from-curelab-oncology-achieves-significant-reduction-in-mortality-and-an-increase-in-overall-survival-in-platinum%e2%80%91resistant-ovarian-cancer-bioquick/2026-02-24T08:02:38+00:00https://www.curelaboncology.com/novel-dna-therapy-elenagen-shows-promise-for-platinum-resistant-ovarian-cancer/2026-02-24T08:07:46+00:00https://www.curelaboncology.com/a-novel-dna-based-therapy-achieves-significant-increase-in-overall-survival-in-platinum-resistant-ovarian-cancer-2/2026-02-24T08:22:16+00:00https://www.curelaboncology.com/uma-nova-terapia-baseada-em-dna-alcanca-aumento-significativo-na-sobrevida-global-no-cancer-de-ovario-resistente-a-platina/2026-02-24T08:37:48+00:00https://www.curelaboncology.com/elenagen-phase-ii-data-in-platinum-resistant-oc/2026-02-28T08:26:10+00:00https://www.curelaboncology.com/alexander-shneider-elenagen-combination-extends-survival-in-ovarian-cancer/2026-02-28T08:41:57+00:00https://www.curelaboncology.com/a-plasmid-based-cancer-therapy-dr-alexander-schneider/2026-03-02T19:56:56+00:00https://www.curelaboncology.com/dr-gabriel-levin-on-the-base-to-base-biotech-podcast/2026-03-31T04:49:12+00:00https://www.curelaboncology.com/a-novel-approach-to-platinum-resistant-ovarian-cancer-results-from-the-elenagen-phase-ii-study-esgo-2026/2026-04-13T14:26:52+00:00